Literature DB >> 11115505

Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity.

C M Paumi1, B G Ledford, P K Smitherman, A J Townsend, C S Morrow.   

Abstract

We investigated the role of phase II (conjugation) and phase III (efflux) detoxification of the anticancer drugs melphalan (MLP) and chlorambucil (CHB). Although both drugs are substrates of Alpha-class glutathione S-transferases (GST) and the monoglutathionyl conjugates formed in these enzymatic reactions are transported by MRP1, we found that GSTA1-1 and MRP1 acted in synergy to confer resistance to CHB but not to MLP (Morrow, C. S., Smitherman, P. K., Diah, S. K., Schneider, E., and Townsend, A. J. (1998) J. Biol. Chem. 273, 20114-20120). To explain this selectivity of MRP1/GST-mediated resistance, we report results of side-by-side experiments comparing the kinetics of MLP- versus CHB-glutathione conjugate: formation, product inhibition of GSTA1-1 catalysis, and transport by MRP1. The monoglutathionyl conjugate of CHB, CHB-SG, is a very strong competitive inhibitor of GSTA1-1 (K(i) 0.14 microM) that is >30-fold more potent than that of the corresponding conjugate of MLP, MLP-SG (K(i) 4.7 microM). The efficiency of GSTA1-1-mediated monoglutathionyl conjugate formation is more than 4-fold higher for CHB than MLP. Lastly, both CHB-SG and MLP-SG are efficiently transported by MRP1 with similar V(max) although the K(m) for CHB-SG (0.37 microm) is significantly lower than for MLP-SG (1.1 microM). These results indicate that MRP1 is required for GSTA1-1-mediated resistance to CHB in order to relieve potent product inhibition of the enzyme by intracellular CHB-SG formed. The kinetic properties of MRP1 are well suited to eliminate CHB-SG at pharmacologically relevant concentrations. For MLP detoxification, where product inhibition of GSTA1-1 is less important, GSTA1-1 does not confer resistance because of the relatively poorer catalytic efficiency of MLP-SG formation. Similar analyses can be useful for predicting the pharmacological and toxicological consequences of MRP and GST expression on cellular sensitivity to various other electrophilic xenobiotics.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115505     DOI: 10.1074/jbc.M009400200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Is there a role for tau glutathione transferases in tetrapyrrole metabolism and retrograde signalling in plants?

Authors:  Elodie Sylvestre-Gonon; Mathieu Schwartz; Jean-Michel Girardet; Arnaud Hecker; Nicolas Rouhier
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-05-04       Impact factor: 6.237

2.  A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Donald W Miller
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

3.  Enhanced glutathione depletion, protein adduct formation, and cytotoxicity following exposure to 4-hydroxy-2-nonenal (HNE) in cells expressing human multidrug resistance protein-1 (MRP1) together with human glutathione S-transferase-M1 (GSTM1).

Authors:  Lisa P Rudd; Sandra L Kabler; Charles S Morrow; Alan J Townsend
Journal:  Chem Biol Interact       Date:  2011-09-08       Impact factor: 5.192

4.  Glutathione Conjugation at the Blood-CSF Barrier Efficiently Prevents Exposure of the Developing Brain Fluid Environment to Blood-Borne Reactive Electrophilic Substances.

Authors:  Ingrid Kratzer; Nathalie Strazielle; Elodie Saudrais; Kati Mönkkönen; Céline Malleval; Sandrine Blondel; Jean-François Ghersi-Egea
Journal:  J Neurosci       Date:  2018-03-05       Impact factor: 6.167

5.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

6.  Functional activities and immunohistochemical cellular distribution of glutathione s-transferases in normal, dysplastic, and squamous cell carcinoma human oral tissues.

Authors:  Peter J Giannini; Mark A Morse; Christopher M Weghorst; Ping Pei; Susan R Mallery
Journal:  Clin Med Oncol       Date:  2008-03-28

7.  Noncatalytic interactions between glutathione S-transferases and nitroalkene fatty acids modulate nitroalkene-mediated activation of peroxisomal proliferator-activated receptor gamma.

Authors:  Darcy J P Bates; Mark O Lively; Michael J Gorczynski; S Bruce King; Alan J Townsend; Charles S Morrow
Journal:  Biochemistry       Date:  2009-05-19       Impact factor: 3.162

Review 8.  RLIP76: a versatile transporter and an emerging target for cancer therapy.

Authors:  Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sanjay Awasthi; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2010-01-25       Impact factor: 5.858

Review 9.  Glutathione analogues in cancer treatment.

Authors:  David Hamilton; Gerald Batist
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

10.  NRF2 and the Phase II Response in Acute Stress Resistance Induced by Dietary Restriction.

Authors:  Christopher M Hine; James R Mitchell
Journal:  J Clin Exp Pathol       Date:  2012-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.